New stock news | The prospectus for the listing of English Pharmaceutical in Hong Kong has been invalidated.

Jiangsu Unity Biopharmaceutical Co., Ltd. (referred to as Unity Biopharma) submitted its Hong Kong stock prospectus on September 26, 2025, which expired after 6 months on March 26, 2026. At the time of submission, Goldman Sachs and China International acted as its joint sponsors. According to the previous prospectus, Unity Biopharma was established in 2009 and is a biotechnology company in the commercialization stage, focusing on the global development of precision anticancer therapies based on synthetic lethality mechanisms. The company has established a comprehensive and advanced portfolio of synthetic lethality products and is one of only three companies globally with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors.